PDF(Pubmed)
Abstract：
Gastric cancer (GC) is a leading cause of death, and this pathology often receives a diagnosis in an advanced stage. The development of a less invasive and cost-effective test for detection is essential for decreasing the mortality rate and increasing the life expectancy of GC patients. We evaluated the potential targeting of CD54/ICAM1, a marker of gastric cancer stem cells, with miRNAs to detect GC in blood samples. The analyses included 79 blood samples, 38 from GC patients and 41 from healthy donors, who attended INCan, México City. The total RNA was obtained from the blood plasma, and RT-PCR and qPCR were performed to obtain the relative expression of each miRNA. Hsa-miR-335-5p was detected in the plasma of GC patients and healthy donors at the same levels. The ROC curve analyses indicated that this miRNA was not a candidate for the molecular diagnosis of GC. We did not observe a correlation between the expression of hsa-miR-335-5p and clinical variables; however, the Kaplan-Meier analyses indicated that, in patients who survived more than 12 months, a lower expression of hsa-miR-335-5p was correlated with a better prognosis. It would be convenient to evaluate a larger panel of miRNAs, including miRNAs expressed in a limited number of cell types or with a low number targets, to obtain more specific candidates for developing a robust test for the diagnosis/prognosis of GC.
摘要：
胃癌（GC）是导致死亡的主要原因，这种病理通常在晚期得到诊断。开发侵入性较低且具有成本效益的检测测试对于降低GC患者的死亡率和增加预期寿命至关重要。我们评估了胃癌干细胞标志物CD54/ICAM1的潜在靶向性，用miRNA检测血液样品中的GC。分析包括79份血液样本,38名来自GC患者，41名来自健康捐赠者，谁参加了INCan，墨西哥市.从血浆中获得总RNA，并进行RT-PCR和qPCR以获得每个miRNA的相对表达。在GC患者和健康供体的血浆中检测到相同水平的Hsa-miR-335-5p。ROC曲线分析表明该miRNA不是GC分子诊断的候选物。我们没有观察到hsa-miR-335-5p的表达与临床变量之间的相关性；然而，Kaplan-Meier分析表明，存活超过12个月的患者，hsa-miR-335-5p的低表达与较好的预后相关.评估一组更大的miRNA会很方便，包括在有限数量的细胞类型中表达或具有少量靶标的miRNA，获得更具体的候选人，以开发用于GC诊断/预后的可靠测试。
